Etaracizumab Biosimilar – Anti-ITGAV_ITGB3 mAb – Research Grade from ProteoGenix; catalogue PX-TA1173; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Etaracizumab Biosimilar, also known as Anti-ITGAV_ITGB3 mAb, is a research grade antibody that has been developed as a biosimilar to the commercially available drug, Abciximab. It is a monoclonal antibody that specifically targets the integrin receptor complex, composed of the ITGAV and ITGB3 subunits. This biosimilar has been designed to mimic the structure and function of Abciximab, making it a potential alternative for the treatment of conditions where Abciximab is currently used.
Etaracizumab Biosimilar is a recombinant humanized monoclonal antibody, meaning it is produced using genetic engineering techniques in a laboratory setting. It is composed of two heavy chains and two light chains, each of which is made up of variable and constant regions. The variable regions are responsible for binding to the target protein, while the constant regions provide stability and effector functions.
The structure of Etaracizumab Biosimilar is highly similar to that of Abciximab, with the exception of a few amino acid substitutions. This is important as it allows the biosimilar to maintain its specificity and activity towards its target, while also minimizing the risk of immunogenicity.
Etaracizumab Biosimilar works by binding to the ITGAV_ITGB3 integrin receptor complex on the surface of cells. This receptor complex is involved in cell adhesion and signaling, making it an attractive therapeutic target for a variety of diseases. By binding to this complex, Etaracizumab Biosimilar inhibits its activity, leading to a decrease in cell adhesion and signaling.
One of the key mechanisms of action of Etaracizumab Biosimilar is its ability to block platelet aggregation. This is particularly important in the treatment of conditions such as acute coronary syndrome, where platelet aggregation can lead to the formation of blood clots and potentially life-threatening complications.
Etaracizumab Biosimilar has a wide range of potential applications due to its ability to target the ITGAV_ITGB3 integrin receptor complex. Some of the conditions where this biosimilar may be used include:
In summary, Etaracizumab Biosimilar is a research grade monoclonal antibody that specifically targets the ITGAV_ITGB3 integrin receptor complex. It has a similar structure and mechanism of action to the commercially available drug, Abciximab, and has potential applications in the treatment of a variety of conditions, including acute coronary syndrome, stroke, and cancer. Further research and clinical trials are needed to fully evaluate the efficacy and safety of this biosimilar, but it holds promise as a potential alternative to existing therapies.
ProteoGenix catalogue number PX-TA1173. For research use only.
Target: Etaracizumab Biosimilar – Anti-ITGAV_ITGB3 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB, Flow Cyt.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Etaracizumab Biosimilar – Anti-ITGAV_ITGB3 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
